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The transcriptional regulator SnoN plays a fundamental role as a modulator of transforming growth
factor beta (TGFb)-induced signal transduction and biological responses. In recent years, novel func-
tions of SnoN have been discovered in both TGFb-dependent and TGFb-independent settings in pro-
liferating cells and postmitotic neurons. Accumulating evidence suggests that SnoN plays a dual role
as a corepressor or coactivator of TGFb-induced transcription. Accordingly, SnoN exerts oncogenic or
tumor-suppressive effects in epithelial tissues. At the cellular level, SnoN antagonizes or mediates
the ability of TGFb to induce cell cycle arrest in a cell-type speciﬁc manner. SnoN also exerts key
effects on epithelial-mesenchymal transition (EMT), with implications in cancer biology. Recent
studies have expanded SnoN functions to postmitotic neurons, where SnoN orchestrates key aspects
of neuronal development in the mammalian brain, from axon growth and branching to neuronal
migration and positioning. In this review, we will highlight our understanding of SnoN biology at
the crossroads of cancer biology and neurobiology.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction found in chromatin remodeling proteins including Sp100, AIRE-1,The Sno gene, encoding the protein SnoN, was identiﬁed more
than 20 years ago in a study screening for genes related to the
oncogene c-ski [1]. The identiﬁcation of the human Sno gene was
followed by isolation of orthologues in vertebrates and inverte-
brates including mouse, chicken and Drosophila [2–6]. SnoN came
to prominence when it was shown to be involved in the regulation
of TGFb signaling and cancer biology [7,8]. Recent studies have re-
vealed that SnoN functions extend beyond cycling cells to postmi-
totic neurons [9–12]. In this review, we will focus on the versatile
functions of SnoN and their underlying mechanisms in TGFb-
dependent and independent signaling, tumorigenesis, and brain
development.
Several observations link SnoN’s ability to regulate transcription
to its effects on biological responses [13–15]. Not surprisingly,
SnoN interacts with transcriptional regulators including the Smads
and components of the histone deacetylase (HDAC) complex
[7,8,16]. Biochemical and structural studies have deﬁned speciﬁc
regions, motifs and domains that contribute to SnoN’s interaction
with other proteins. SnoN associates with the TGFb-regulated
signaling proteins Smad2 and Smad3 via a region encompassing
amino acids 88–92 in SnoN [17]. Smad4 associates with SnoN via
the SAND domain, which is approximately 100 amino acids [18].
The SAND domain, located in the N-terminal region of SnoN, is alsochemical Societies. Published by ENucp41/75 and DEAF-1 [18,19]. Although the SAND domain is
thought to mediate DNA binding, SnoN’s SAND domain is proposed
to promote structural stability rather than DNA binding [18]. N-
terminal to the SAND domain is the dac/ski/sno domain in SnoN,
which is approximately 100 amino acids long. The ski/sno/dac do-
main has a globular structure with ﬁve b-sheets and four a-helices,
and recent crystallography data of this domain reveal a groove
with open and closed conformations that may provide a protein
interaction platform [20]. SnoN is proposed to interact via its ski/
sno/dac domain with the transcriptional corepressor NCoR, a com-
ponent of the HDAC complex [16]. The ski/sno/dac domain also
contains the motif RxxLxxxxN, which is a recognition motif for
the ubiquitin ligase Cdh1–anaphase promoting complex (Cdh1–
APC) [21]. The C-terminus of SnoN is characterized by a-helical re-
peats that form a coiled-coil region [22–25]. This region confers
SnoN with the ability to form homodimers or heterodimers with
Ski [22–26]. Overall, these biochemical studies suggest that dis-
tinct regions within SnoN mediate associations with different pro-
teins that play important roles in SnoN-dependent cellular
functions.
2. SnoN functions in proliferating cells
Since its identiﬁcation in the late 80s, SnoN has been the subject
of intense investigation. Several lines of evidence suggest that
SnoN plays essential roles in TGFb-dependent signaling, though
SnoN also harbors TGFb-independent functions.lsevier B.V. All rights reserved.
Fig. 1. SnoN functions in TGFb-induced transcription and cellular responses. (a)
SnoN promotes TGFb-induced transcription and biological responses by acting as an
adaptor inducing a Smad–SnoN–ING2 multiprotein complex on promoters of TGFb-
responsive genes. (b) Sumoylation is critical for the ability of SnoN to inhibit TGFb-
induced EMT. In epithelial cells, the SUMO E3 ligase PIAS1 sumoylates SnoN and
thereby maintains the expression of epithelial markers and phenotype. Activation
of TGFb pathway results in the degradation of PIAS1 and subsequent reduction in
the level of sumoylated SnoN, thus facilitating EMT.
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SnoN has critical roles in regulating signaling and responses by
the TGFb family of cytokines. TGFbs exerts pleiotropic effects in
multicellular organisms that are essential for normal development
and homeostasis [27,28]. The Smad signaling pathway represents
the canonical mechanism by which TGFb triggers its biological re-
sponses. TGFb initiates signaling by forming an active heteromeric
complex with cell surface type I and type II ser/thr kinase receptors
[27,29]. The activated ligand-receptor complex in turn stimulates
receptor regulated-Smad2/3 (R-Smad2/3) phosphorylation and
association with the common partner Smad4 [30]. The R-Smad2/
3-Smad4 complex translocates to the nucleus, binds to speciﬁc
DNA Smad binding elements (SBE) within TGFb-responsive genes,
and regulates transcription [31–33].
SnoN associates with Smad2/3 and Smad4, and is recruited to
TGFb responsive genes, and thus inﬂuences their transcription
[7]. When overexpressed, SnoN inhibits transcription of genes reg-
ulated by the TGFb–Smad signaling pathway [7,8]. To relieve SnoN-
inhibition of transcription, TGFb signaling induces the degradation
of SnoN protein by the ubiquitin–proteasome pathway [7,8]. The
ubiquitin ligases Cdh1–anaphase promoting complex (Cdh1–
APC), Smurf2, and Arkadia mediate the ability of TGFb to induce
the ubiquitination and consequent degradation of SnoN [17,34–
37]. Remarkably, simultaneously with inducing SnoN degradation,
TGFb stimulates SnoN transcription. Once expressed, SnoN acts as
a negative feedback inhibitor of TGFb signaling [7].
Although the prevailing view holds that SnoN acts as a core-
pressor with the Smad proteins, several studies have demonstrated
that SnoN also acts as a transcriptional coactivator and thus medi-
ates TGFb-induced transcription in a cell type- and context-depen-
dent manner [12,38,39]. Accordingly, knockdown of SnoN in
epithelial cells and primary granule neurons reduces TGFb-depen-
dent transcription and the expression of TGFb-responsive genes
[12,38,39]. Consistent with this idea, the Drosophila SnoN ortho-
logue, dSno, collaborates with the Drosophila Smad4 orthologue,
Medea, to mediate TGFb responses in the Drosophila nervous sys-
tem [6]. Thus, the ability of SnoN to facilitate TGFb-induced tran-
scription and responses is evolutionary conserved. Collectively,
these observations suggest that SnoN has dual roles in the regula-
tion of transcription. The nature of SnoN function as a transcrip-
tional corepressor or coactivator may be determined in a cell
type- or target gene-speciﬁc manner.
What are the cellular consequences of SnoN’s effects on tran-
scription? Paralleling the dual effects of SnoN on TGFb-induced
transcription, SnoN exerts opposing effects on TGFb-induced cell
cycle arrest. When overexpressed, SnoN antagonizes TGFb-induced
cell cycle arrest [7,17,40]. Consistent with these results, overex-
pressed SnoN transforms chick embryo ﬁbroblasts [2,22]. However,
mouse embryonic ﬁbroblasts (MEFs) and T-lymphocytes deﬁcient
in SnoN due to the disruption of one sno allele (sno±) have in-
creased rates of proliferation, suggesting that SnoN inhibits cell
proliferation [41]. In agreement with these results, SnoN promotes
the ability of TGFb to induce cell cycle arrest [39]. Thus, these data
suggest that SnoN mediates TGFb-induced transcription and cell
cycle arrest.
SnoN also regulates epithelial-mesenchymal transition (EMT)
[42,43]. EMT is a fundamental biological process in which epithe-
lial cells lose apical–basal polarity, cell–cell contact and epithelial
markers, undergo cytoskeletal reorganization and mesenchymal
differentiation, and become migratory [44,45]. TGFb is a well-
established inducer of EMT, with important consequences in devel-
opment, wound healing, and cancer progression [46–48]. In view
of its signiﬁcance in development and disease, TGFb-induced
EMT has garnered substantial attention. The non-transformed
NMuMG mammary epithelial cells represent a widely used modelfor studies of TGFb-induced EMT [49–51]. SnoN strongly sup-
presses the ability of TGFb to induce EMT in NMuMG cells as char-
acterized by reduction in TGFb-induced loss of E-cadherin levels,
and acquisition of ﬁbroblastic phenotype [42]. Consistent with
these results, SnoN mediates resistance to TGFb-induced EMT in
MDA-MB-231 breast and A549 lung carcinoma cells [43].
2.2. Molecular mechanisms of SnoN functions in TGFb signaling
The mechanisms by which SnoN regulates TGFb-induced tran-
scription have been investigated, though they remain incompletely
understood. Several mechanisms have been proposed to explain
how SnoN inhibits TGFb-induced transcription. SnoN recruits an
HDAC transcriptional corepressor complex to TGFb-responsive
genes [13,15]. It has also been proposed that by associating with
Smad4, SnoN may disrupt Smad4 interaction with Smad2/3 and
consequent gene expression [18]. Although SnoN is predominantly
nuclear, it may also localize in the cytoplasm in some cell types
[52,53]. Within the cytoplasm, SnoN interacts with the Smads
and blocks their nuclear translocation and induction of target gene
transcription [52]. The mechanisms by which SnoN mediates
TGFb-induced transcription are also beginning to be characterized.
In its capacity as a transcriptional coactivator, SnoN forms a com-
plex with the chromatin remodeling protein ING2, which promotes
TGFb-induced transcription and cell cycle arrest ([38], Fig. 1a).
ING2 contains a plant homeodomain (PHD) zinc ﬁnger that recog-
nizes and binds the Lysine 4 trimethylated motif within histone H3
[54–56]. Interestingly, ING2 interacts via its PHD domain with
SnoN [38]. SnoN thus promotes the formation of a Smad2-SnoN-
ING2 transcriptional complex (Fig. 1a). Accordingly, ING2 and
SnoN collaborate to promote TGFb-induced transcription (Fig. 1a).
As might be anticipated in view of SnoN’s profound effects on
the cell cycle and EMT, SnoN is tightly regulated in proliferating
cells. SnoN is controlled by ubiquitination and consequent degra-
dation by the proteasome pathway. Several ubiquitin E3 ligases
including Cdh1–APC and Smurf2 induce the ubiquitination of SnoN
[17,34,37]. In addition to ubiquitination, SnoN is regulated by
sumoylation [57,58]. The SUMO E3 ligase PIAS1 promotes the
sumoylation of SnoN at Lysine 50 and 383 [57]. Notably, PIAS1 pro-
tein is downregulated by TGFb in cells undergoing EMT ([42],
Fig. 1b). Consequently, the levels of sumoylated SnoN are de-
creased dramatically during EMT. Conversely, PIAS1 and sumoylat-
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of wild type PIAS1, but not ligase inactive PIAS1, or the expression
of wild type SnoN, but not SUMO loss of function SnoN mutants,
suppresses TGFb-induced EMT. The identiﬁcation of the PIAS1-
SnoN sumoylation pathway as a mechanism that controls TGFb-in-
duced EMT has raised several questions including how TGFb
regulates the levels of PIAS1 and the mechanisms by which sumoy-
lated SnoN suppresses EMT.
2.3. TGFb-independent functions of SnoN
In addition to its role in TGFb-mediated signaling and re-
sponses, the biological functions of SnoN in proliferating cells
may involve other signaling pathways. SnoN promotes replicative
senescence in MEFs and ovarian epithelial cells [59,60]. Knockin
MEFs expressing a Smad-binding defective SnoN protein suggest
that SnoN promotes senescence independently of Smad binding
[60]. SnoN-induced senescence in MEFs may occur via p53 and
PML-dependent mechanisms [60]. However, stable expression of
exogenous SnoN in ovarian epithelial cells induces senescence in
a p53- and PML-independent manner [59]. Differences in the re-
sults of these two studies may be related to cell type and mode
of SnoN expression. SnoN may also play a role in estrogen recep-
tor-mediated signaling and responses in a TGFb-independent set-
ting [61]. SnoN interacts via conserved nuclear receptor binding
LxxLL-like motifs with ligand-activated estrogen receptor alpha
(ERa). SnoN occupies the ER-responsive promoter elements and
induces the expression of the ERa target gene thyroid transcription
factor 1 (TTF1) [61]. SnoN associates with the transcriptional coac-
tivator p300 [12,61], and recruits it to ligand-induced ERa [61],
leading to activation of transcription.
3. Role of SnoN in neoplastic diseases
With functions in cell cycle progression, EMT, and senescence in
proliferating cells, SnoN has emerged as a key target in tumorigen-
esis. Studies over the last several years have revealed that SnoN
may have complex roles in cancer.
3.1. SnoN as an oncogene
SnoN regulation of TGFb-mediated responses has important
implications for how SnoN inﬂuences cancer pathology. An impor-
tant cellular hallmark of cancer is resistance to cytostatic signals
[62,63]. The ability of TGFb to inhibit cell proliferation of distinct
cell types including epithelial and hematopoietic cells suggests
that the TGFb–Smad pathway suppresses initiation and early pro-
gression of tumorigenesis [64–66]. Accordingly, several types of
cancers including mammary, colorectal and pancreatic carcinomas
acquire resistance to TGFb-induced cell cycle arrest [64–66]. The
ability of overexpressed SnoN to inhibit TGFb-induced transcrip-
tion and cell cycle arrest supports a potential role for SnoN in onco-
genic transformation of cells. SnoN is upregulated in several types
of cancer including melanomas, esophageal and breast carcinomas
[43,67–70]. In addition, upregulated SnoN levels correlate with the
degree of invasion and poor prognosis of esophageal squamous cell
carcinomas [71,72]. Several mechanisms including chromosomal
ampliﬁcation and increased protein stability have been proposed
to increase SnoN levels in carcinomas [59,71]. SnoN is a relatively
short-lived protein and targeted to degradation by the ubiquitin–
proteasome pathway. Thus, dysfunction in speciﬁc ubiquitin li-
gases may lead to the accumulation of SnoN protein [59,73]. In
summary, at early stages of cancer, increased levels may allow
SnoN to act as an oncogene by inhibiting TGFb-induced transcrip-
tion and responses.3.2. SnoN as a tumor suppressor
Although SnoN is largely characterized as an oncogenic protein,
SnoN also operates in a tumor-suppressive manner. Heterozygous
sno ± mice develop tumors spontaneously or upon exposure to car-
cinogenic agents [41]. Consistent with a tumor-suppressive role,
MEFs, T and B cell lymphocytes derived from sno ± mice show en-
hanced rates of proliferation and suppression of apoptosis com-
pared to cells derived from wild type control mice [41].
An important cellular hallmark of cancer is the re-initiation of
the process of EMT [44,45]. This program of dedifferentiation is
critical for the ability of cancer cells to migrate and form new tu-
mors at distant secondary sites. At the later stages of tumorigene-
sis, cancer cells utilize the ability of TGFb to induce EMT to their
advantage [48,64,65]. Thus, TGFb-mediated pathways can act as
tumor promoters later in cancer. Inhibition of TGFb-induced EMT
by SnoN suggests the possibility that SnoN may oppose cancer pro-
gression. Accordingly, SnoN has been suggested to inhibit tumor
invasion at the later stages of cancer [43]. The role of EMT in pro-
moting cancer cell migration raises the possibility that the ability
of SnoN to oppose EMT might be dynamically regulated in cancer
cells. Reduction in SnoN levels by the ubiquitin pathway or inhibi-
tion of SnoN activity could provide the means to promote EMT. The
recently identiﬁed role of the SUMO E3 ligase PIAS1 and SnoN
sumoylation in inhibiting TGFb-induced EMT raises the important
question of whether sumoylation contributes to SnoN antagonism
of EMT in cancer cells, and if so, whether downregulation of PIAS1
relieves the negative effect of SnoN sumoylation on EMT and can-
cer progression. Thus, it will be important to investigate the signif-
icance of regulation of the PIAS1–SnoN sumoylation pathway in
cancer invasion and metastasis.
The tumor-suppressive function of SnoN may also be partly re-
lated to participation in TGFb-independent signaling. Induction of
senescence in MEFs by Smad-defective SnoN and involvement of
the tumor suppressor p53 and its positive regulator PML in this re-
sponse suggest that SnoN may cooperate together with p53 and
PML to suppress tumorigenesis [60]. SnoN may also induce senes-
cence independently of p53 and PML [59]. Intriguingly, the chro-
matin remodeling proteins ING1 and ING2 promote senescence
in both p53-dependent and independent mechanisms [74–76].
Thus, it is tempting to speculate that ING2 may also contribute
to the ability of SnoN to induce senescence and hence tumor
suppression.
In sum, studies of SnoN in proliferating cells point to complex
roles of SnoN in tumor initiation and progression. Different factors
including the level of SnoN expression and phase of cancer may
contribute to the type of effect that SnoN may have on tumorigen-
esis. The ability of SnoN to regulate TGFb-mediated signaling and
responses appears to form the basis of many of SnoN’s effects in
cancer.
4. SnoN functions in postmitotic neurons
Although SnoN functions have been the subject of intense
investigation in proliferating cells and in the context of cancer biol-
ogy, the expression of SnoN in the mammalian brain has raised the
important question of whether SnoN harbors functions in postmi-
totic neurons. In recent years, novel roles for SnoN in several facets
of neuronal development have been uncovered.
4.1. SnoN as a critical regulator of axon morphogenesis
Much of our current understanding of SnoN function in the ner-
vous system has come from studies of the rodent cerebellar cortex,
and in particular cerebellar granule neurons [77,78]. Granule
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the external granule layer (EGL) of the developing rodent cerebel-
lum [79–83]. Once generated, granule neurons extend axons that
eventually form parallel ﬁbers within the molecular layer of the
cerebellar cortex. Along with axon development, the soma of the
developing granule neuron migrates inward from the EGL, across
the molecular layer, past the Purkinje cell layer, and into the inter-
nal granule layer (IGL). Once in the IGL, granule neurons extend
dendrites, which undergo growth and branching, pruning, and
postsynaptic dendritic differentiation. The features of axon devel-
opment, migration, and dendrite morphogenesis have been well
characterized and widely studied in granule neurons, making these
neurons ideal for the study of the molecular mechanisms of neuro-
nal morphogenesis and differentiation in the developing brain
[77,84]. Granule neuron development can be studied in vivo, in
organotypic cerebellar slices, and in primary culture.
Advances in understanding SnoN function in the nervous sys-
tem have been gained in the context of axon development
(Fig. 2a). Knockdown of SnoN in primary granule neurons leads
to profound impairment of axon growth [10]. Time-lapse studies
in primary granule neurons suggest that SnoN promotes the elon-
gation of axons [10]. Knockdown of SnoN in granule neurons in rat
pups, using an in vivo electroporation method designed speciﬁcally
for the cerebellar cortex, leads to profound loss of parallel ﬁber ax-
ons in the cerebellar cortex [10]. The loss of parallel ﬁber axons in
SnoN-knockdown rat pups may result from the inability of axons
to elongate or from their destabilization.
The regulation of SnoN function in axon development has been
characterized, though undoubtedly these mechanisms are incom-
pletely understood (Fig. 2a). The ubiquitin ligase Cdh1–APC stimu-
lates the ubiquitination and consequent degradation of SnoN in
neurons and thereby limits axon growth ([10], Fig. 2a). Accord-
ingly, Cdh1–APC operates in the nucleus of developing neurons
to restrict axon growth [10,85]. Cdh1 knockdown in rat pups leads
to defasciculation of parallel ﬁber axons [86], suggesting that
Cdh1–APC also controls the patterning of axons beyond simply
restricting their growth. However, SnoN may not participate in
the control of axon patterning downstream of Cdh1–APC [10].
The ability of neuronal Cdh1–APC to stimulate the degrada-
tion of SnoN is stimulated by activation of TGFb–Smad2 signal-Fig. 2. SnoN has versatile functions in the mammalian brain. (a) SnoN promotes
axons growth in postmitotic neurons. SnoN associates with the transcriptional
coactivator p300 to induce transcription of the Ccd1 gene, which has a critical role
in axon growth. SnoN-induced axon growth is controlled by the ubiquitin ligase
Cdh1–APC, which is recruited to SnoN by the TGFb–Smad pathway. (b) The SnoN
isoforms, SnoN1 and SnoN2, have opposing roles in the coordinate regulation of
neuronal branching and migration. SnoN1 promotes neuronal branching and
inhibits neuronal migration. SnoN2 inhibits the ability of SnoN1 to control neuronal
branching and migration. SnoN1 associates with the transcription FOXO1 to repress
the expression of the DCX gene.ing in neurons ([11], Fig. 2a). Accordingly, TGFb–Smad2
signaling restricts axon growth in granule neurons [11]. Con-
versely, inhibition of TGFb signaling stimulates axon growth,
including when myelin with its potent axon-inhibitory activities
is used as the cellular substrate in cultures of primary granule
neurons [11]. These ﬁndings raise the intriguing possibility that
inhibition of TGFb signaling may promote axon regeneration in
neurons following injury.
The mechanisms by which SnoN promotes axon growth are also
beginning to be elucidated (Fig. 2a). Microarray analyses of SnoN-
knockdown granule neurons have revealed that the majority of al-
tered genes are downregulated, suggesting that SnoN may act as a
transcriptional coactivator [12]. Consistent with this idea, SnoN
associates with the transcriptional coactivator p300 ([12],
Fig. 2a). Knockdown of p300 inhibits axon growth, phenocopying
the effect of SnoN knockdown [12]. The actin-binding protein
Ccd1 has been uncovered as a critical SnoN-regulated target gene
in neurons ([12], Fig. 2a). Ccd1 localizes to axon terminals, and loss
of function studies suggest that Ccd1 mediates SnoN-dependent
axon growth in granule neuron [12]. SnoN and p300 are both re-
quired for Ccd1 transcription in neurons (Fig. 2a). Collectively,
studies of SnoN have deﬁned an intricate cell-intrinsic transcrip-
tional pathway that controls the growth of axons.
4.2. Isoform-speciﬁc roles of SnoN in neuron branching, migration and
positioning
SnoN is not just one protein, but rather two proteins, SnoN1 and
SnoN2, that are the products of two alternatively spliced-forms of
Sno mRNA. The two SnoN proteins differ by a stretch of 46 amino
acids found in SnoN1 but not SnoN2 [15]. SnoN1 and SnoN2 are
both expressed in neurons [9,10], raising the question of whether
the SnoN isoforms have redundant or non-redundant functions.
Isoform-speciﬁc knockdown of SnoN isoforms has revealed that
SnoN1 and SnoN2 operate redundantly in axon growth ([9],
Fig. 2a). However isoform speciﬁc knockdown of the SnoN isoforms
has also revealed non-redundant functions of SnoN1 and SnoN2
([9], Fig. 2b). Knockdown of SnoN2, but not SnoN1, leads to exuber-
ant branching of axons in primary granule neurons [9]. Remark-
ably, knockdown of SnoN1 in the context of SnoN2 silencing
suppresses the axon branching phenotype. These data suggest that
SnoN1 stimulates excessive axon branching, and SnoN2 antago-
nizes SnoN1-dependent branching (Fig. 2b).
Increasing evidence suggests that impaired neuronal migration
is associated with excessive branching in primary neurons [87–90].
Consistent with this idea, knockdown of SnoN2 in vivo inhibits
migration of granule cells from the external granule layer (EGL)
to the internal granule layer (IGL) of the cerebellar cortex [9].
Knockdown of SnoN1 reverses the SnoN2 knockdown-induced cell
migration phenotype. These data suggest that just as in the control
of branching, SnoN1 and SnoN2 have opposing functions in the
control of neuron migration from the EGL into the IGL in the cere-
bellar cortex (Fig. 2b).
Once granule neurons reach the IGL from the EGL, they journey
farther within the IGL to reach their ﬁnal position with the older
neurons settling in deeper regions inside the IGL and younger neu-
rons residing in more superﬁcial regions [79,91]. The establish-
ment of neuronal positioning is critical for normal brain
functions. Although the migration of granule neurons from the
EGL to the IGL has been studied widely, the positioning of neurons
within the IGL is just beginning to be investigated. SnoN control of
neuronal positioning extends beyond their migration from the EGL
to the IGL [9]. Remarkably, knockdown of SnoN1 increases the
number of granule neurons residing within deeper areas of the
IGL, suggesting that SnoN1 is required for proper granule neuron
positioning [9].
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branching and positioning in the cerebellar cortex? Since SnoN is a
transcriptional co-regulator, the SnoN isoforms would be expected
to function together with a DNA-binding transcription factor to reg-
ulate neuronal branching and positioning. Recent studies suggest
that SnoN1 forms a speciﬁc complex with the transcription factor
FOXO1 and thereby regulates neuronal branching and positioning
([9], Fig. 2b). In reporter assays, SnoN1 represses FOXO-dependent
transcription. Consistent with opposing roles of the SnoN isoforms
in neuronal branching andmigration, SnoN2 antagonizes the ability
of SnoN1 to repress FOXO-dependent transcription ([9], Fig. 2b). The
interaction of FOXO1with SnoN1 is functionally relevant, as knock-
down of FOXO1 in rat pups phenocopies the effect of SnoN1 knock-
down on the positioning of granule neurons in the IGL [9]. These
results suggest that SnoN1 and FOXO1 form a transcriptional core-
pressor complex that regulates neuronal positioning.
If SnoN1 and FOXO1 form a transcriptional repressor complex,
what are the target genes that mediate the ability of this complex
to control neuronal migration? Although these targets remain to be
identiﬁed, one good candidate is the X-linked gene encoding the
microtubule associated protein doublecortin (DCX) ([9], Fig. 2b).
Mutations of DCX represent an important cause of X-linked mental
retardation and epilepsy [92–94]. Notably, inhibition of DCX im-
pairs migration and stimulates neuronal branching [87,89,95,96].
Remarkably, FOXO1 and SnoN occupy regulatory sequences of
the DCX gene and knockdown of FOXO1 or SnoN1 derepresses
DCX expression [9]. These ﬁndings suggest that DCX represents a
direct target of the SnoN1–FOXO1 transcriptional repressor
complex. Accordingly, knockdown of DCX suppresses SnoN1
knockdown-induced phenotypes of neuronal migration and
branching. A model can be envisaged to explain the isoform spe-
ciﬁc role of sno gene products in neuron branching, migration
and positioning, whereby SnoN1 is recruited by FOXO1 to the
target gene DCX to repress its transcription, and this cell-intrinsic
pathway is under negative regulation by SnoN2 (Fig. 2b).
Collectively, recent studies have revealed that SnoN is a critical
player in distinct biological processes within the mammalian brain
including axon growth, branching, and neuronal positioning
(Fig. 2). SnoN regulation of these distinct processes in postmitotic
neurons is intimately linked to its ability to form multiprotein
transcriptional complexes that positively or negatively regulate
transcription. The newly identiﬁed functions of SnoN in neurons
have important implications for brain development and function.5. Conclusions and perspectives
The transcriptional co-regulator SnoN is a critical and versatile
regulator of TGFb-induced transcription and responses. SnoN con-
trols TGFb-mediated responses by acting as a transcriptional core-
pressor or transcriptional coactivator. The mechanisms of
transcriptional activation are beginning to be elucidated. However,
further research is required to elucidate these mechanisms. For
example, unbiased approaches should be used to identify novel
SnoN-interacting proteins that modulate SnoN-dependent tran-
scription. The physiological signiﬁcance of SnoN regulation of
TGFb-induced cell cycle arrest and EMT should be addressed by
employing SnoN loss and gain function approaches in different
model systems including 3D cultures and in vivo. As EMT is a fun-
damental process during different stages of embryonic develop-
ment including gastrulation, neural crest migration and heart
valve formation, it will be important to characterize the role of
SnoN in these processes using conditional sno knockout or knockin
animal models [45].
SnoN has established roles in cancer biology. The emerging
picture is that SnoN exerts a dual role in cancer, i.e. as a tumorpromoter or suppressor depending on various factors including
the stage of cancer and the level of SnoN expression. An important
goal of future studies should be to understand the mechanisms
that mediate the two opposing roles of SnoN in cancer including
identiﬁcation of upstream regulators and downstream effectors
in the regulation of tumorigenesis using in vivo xenograft and
transgenic in vivo models of cancer. Increasingly, it is becoming
clear that the tumor microenvironment, vascular and immune sys-
tems play important roles in cancer initiation and progression [63].
Whether regulation of SnoN-mediated effects in non-tumor de-
rived cells can modulate the ability of TGFb to control tumorigen-
esis remains to be addressed.
SnoN is also emerging as a critical cell-intrinsic regulator of dis-
tinct biological processes in the developing mammalian brain,
though in many ways the recent reports on this subject represent
the tip of the iceberg on the roles and mechanisms of SnoN in neu-
robiology. Nevertheless, we can draw several important conclu-
sions from these studies. SnoN appears to play an essential role
in the control of axon growth. In this function, the two closely re-
lated isoforms of SnoN, SnoN1 and SnoN2, operate in a redundant
manner to activate transcription including the gene encoding the
signaling molecule Ccd1. How SnoN acts as a transcriptional coac-
tivator in neurons remains to be elucidated, though interaction
with p300 appears to play a role. The transcription factor and other
associated factors, besides p300, that cooperate with both SnoN1
and SnoN2 to induce transcription remain to be identiﬁed. In addi-
tion, the role of additional target genes beyond Ccd1 in the control
of axon growth is an area that requires attention. Whether addi-
tional enzymes, besides the ubiquitin ligase Cdh1–APC, regulate
SnoN function in axon growth has not been explored. Finally, the
role of SnoN in axon growth in other regions of the brain beyond
the cerebellar cortex is an important question. Initial studies sug-
gest that SnoN is also required for axon growth in hippocampal
neurons [10]. However, a thorough study of this question requires
a mouse genetics approach. The generation of transgenic mice
expressing SnoN or knockout mice in which the sno gene is dis-
rupted will facilitate studies of SnoN in axon growth in circum-
stances other than development including in the potential for
SnoN to promote axon regeneration following injury and disease.
The isoform speciﬁc functions of SnoN1 and SnoN2 in the con-
trol of neuronal branching andmigration is an excellent example of
how the functions of alternatively spliced protein products that op-
pose each other may be hidden from view if one focuses on com-
plete knockouts or knockdowns of a protein. In future studies, it
will be interesting to determine how the SnoN1–FOXO1 repressor
complex operates in neurons. How is this complex regulated in
neurons, and what are the downstream target genes that are re-
pressed in the control of neuronal positioning?
While studies of SnoN in cancer biology and neurobiology have
been proceeding in parallel, there are likely many interesting links
between the two. For example, the regulation of SnoN by Cdh1–
APC operates both in the control of the G1 phase of the cell cycle
in proliferating and in postmitotic neurons in the control of axon
growth [10,17,37]. Likewise, the control of SnoN by the TGFb–
Smad2 signaling pathway represents a cassette that functions both
in cycling cells and postmitotic neurons, albeit with different bio-
logical responses [7,10,17,34,37]. Extrapolating from these links,
it is tempting to speculate that sumoylation of SnoN or its interac-
tion with the chromatin remodeling protein ING2 in the control of
EMT and cell proliferation in cycling cells may have important yet
to be identiﬁed roles in postmitotic neurons. Conversely, the newly
deﬁned isoform speciﬁc functions of SnoN1 and SnoN2 and the
identiﬁcation of the SnoN1–FOXO1 transcriptional repressor com-
plex in neurons may have important functions in proliferating cells
and tumorigenesis. Progress in SnoN biology in the years ahead
should lead to advances in both cancer biology and neurobiology.
1982 S. Bonni, A. Bonni / FEBS Letters 586 (2012) 1977–1983Ultimately, improved understanding of SnoN holds the prospect for
the development of novel drugs that target diverse diseases includ-
ing cancer and neurological diseases.
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